Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects
Open Access
Abstract
Primary pulmonary hypertension (PPH), now known as pulmonary arterial hypertension (PAH), has induced significant treatment breakthroughs in the past decade. Treatment has focused on improving patient survival and quality of life, and delaying disease progression. Current therapies are categorized based on targeting different pathways known to contribute to PAH, including endothelin receptor antagonists (ERAs), phosphodiesterase-5 inhibitors (PDE-5 inhibitors), prostacyclin analogs, soluble guanylate cyclase stimulators, and activin signaling inhibitors such as Sotatercept. The latest addition to treatment options is soluble guanylate cyclase stimulators, such as Riociguat, which directly stimulates the nitric oxide pathway, facilitating vasodilation. Looking to the future, advancements in PAH treatment focus on precision medicine involving the sub-stratification of patients through a deep characterization of altered Transforming Growth Factor-β(TGF-β) signaling and molecular therapies. Gene therapy, targeting specific genetic mutations linked to PAH, and cell-based therapies, such as mesenchymal stem cells, are under investigation. Besides prevailing therapies, emerging PH treatments target growth factors and inflammation-modulating pathways, with ongoing trials assessing their long-term benefits and safety. Hence, this review explores current therapies that delay progression and improve survival, as well as future treatments with curative potential.Keywords
All Related Versions
This publication has 136 references indexed in Scilit:
- Navigating the Sotatercept landscape: A meta‐analysis of clinical outcomesClinical Cardiology, 2023
- BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertensionPulmonary Circulation, 2022
- Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial HypertensionChest, 2021
- Predicting Survival in Patients With Pulmonary Arterial HypertensionChest, 2019
- Phosphodiesterase 5 inhibitors for pulmonary hypertensionCochrane Database of Systematic Reviews, 2019
- Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling StudyPharmacoEconomics, 2016
- Four- and Seven-Year Outcomes of Patients With Congenital Heart Disease–Associated Pulmonary Arterial Hypertension (from the REVEAL Registry)The American Journal of Cardiology, 2014
- Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term ResultsThe Annals of Thoracic Surgery, 2012
- Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart DiseaseThe American Journal of Cardiology, 2011
- Stem Cells, the Molecular Circuitry of Pluripotency and Nuclear ReprogrammingCell, 2008